26938-87-4

Upstream product

• 143-33-9 sodium cyanide 

Downstream Products

• 913653-27-7 (2-{2-[2-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-1,3-oxazol-4-yl]-3H-benzimidazol-5-yl}ethyl)dimethylamine hydrochloride 
• 913652-84-3 2-(2-(2-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-1,3-oxazol-4-yl)-3H-benzimidazol-5-yl)ethanol 
• 913685-82-2 C₂₁H₂₀ClN₃O₂ 
• 913652-21-8 methyl 2-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-1,3-oxazole-4-carboximidoate hydrochloride 
• 913650-17-6 methyl 2-((5-chloro-2-[(2-methylpropyl)oxy]phenyl)methyl)-4,5-dihydro-1,3-oxazole-4-carboxylate 
• 913650-19-8 methyl 2-((5-chloro-2-[(2-methylpropyl)oxy]phenyl)methyl)-1,3-oxazole-4-carboxylate 
• 913652-16-1 2-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-1,3-oxazole-4-carbonitrile 
• 913651-30-6 2-((5-chloro-2-[(2-methylpropyl)oxy]phenyl)methyl)-1,3-oxazole-4-carboxylic acid 
• 913650-08-5 methyl 2-(5-chloro-2-[(2-methylpropyl)oxy]phenyl)ethanimidoate hydrochloride 

Relevant academic research and scientific papers

OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS

Compounds of formula (I) or a pharmaceutiically acceptable derivative thereof: wherein X, Z, Y', Y'', R1 ,R2a, R2b, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.